Both semaglutide and tirzepatide have not been studied extensively in pregnant women, but animal studies suggest potential risks to fetal development, including: Fetal growth restriction Structural abnormalities Miscarriage (observed in animal studies at high doses) Stillbirth, animal studies show risk at all doses
Its essential to speak with a healthcare professional to see if youre a suitable candidate
The SELECT Trial: Design and Key Findings The SELECT trial enrolled 17,604 patients aged 45 or older with a BMI of 27 or greater and established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral artery disease), but critically, none had diabetes .[1] This design was intentionalresearchers wanted to understand whether semaglutide's cardiovascular benefits extended beyond its known effects in diabetic populations
This retrospective cohort study analyzed data from over 4.8 million adults with type 2 diabetes collected from the TriNetX US Collaborative Network between 2015 and 2022
Dosage chart: 4.0 mL reconstitution (2.5 mg/mL) This is the precision option